Experienced immunologist and cell therapy scientist with a strong background in molecular biology. Skilled in leading research projects, conducting complex experiments, and analyzing data. Proven expertise in project management, multi-parametric flow cytometry, in vitro assays, cell culture, and gene editing. Collaborates effectively with multidisciplinary teams and communicates findings to diverse audiences.
- Postdoctoral research focused on improving persistence, fitness, and functionality of chimeric antigen receptor (CAR)-T cell therapies for treating hematologic malignancies.
- Independently coordinate, design, and execute research projects in the laboratory, performing cutting-edge techniques such as CRISPR/Cas9, RNA-seq, RT-qPCR, ELLA, multiparametric flow cytometry, real-time cell analysis, and in vivo imaging.
- Expertise with pre-clinical in vitro and in vivo potency and safety studies. Experience with humanized mouse models for FDA approval.
- Analyze scientific data, create figures, prepare, and present results at internal and external meetings.
- Mentor and train undergraduate and graduate students.
- Networking Chair of the Moffitt Postdoctoral Association (MPDA) (2023 to present), orchestrating engaging social and networking gatherings aimed at enhancing the professional growth of Moffitt Trainees.
- Class planning and preparation of slide decks.
- Lecturing, presentation of materials, and activities.
- Preparation and correction of exams, including review.
- Classroom engagement through communication and public speaking skills.
- Analyzed complex scientific data, providing insights into cancer immunology and immunotherapy.
- Designed and performed in vitro, ex vivo, and in vivo experiments (murine models of cancer).
- Presented findings at internal and external (national and international) meetings and conferences, facilitating scientific exchange and knowledge dissemination.
* Fortuna GG, Banerjee R, Savid-Frontera C*, et al. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J. 2024;14(1):180. Published 2024 Oct 16. doi:10.1038/s41408-024-01167-8, , October 2024.
* Viano ME, Baez NS, Savid-Frontera C, et al. Systemic inflammatory Th1 cytokines during Trypanosoma cruzi infection disrupt the typical anatomical cell distribution and phenotypic/functional characteristics of various cell subsets within the thymus. Microbes Infect. 2024;26(5-6):105337. doi:10.1016/j.micinf.2024.105337, July 2024.
* Holtan SG, Savid-Frontera C*, Walton K, et al. Human Effectors of Acute and Chronic GVHD Overexpress CD83 and Predict Mortality. Clin Cancer Res. 2023 Mar 14;29(6):1114-1124. doi: 10.1158/1078-0432.CCR-22-2837. PMID: 36622700; PMCID: PMC10011883., March 2023.
* Viano ME, Baez NS, Savid-Frontera C, et al. Virtual Memory CD8+ T Cells: Origin and Beyond. J Interferon Cytokine Res. 2022;42(12):624-642. doi:10.1089/jir.2022.0053, , December 2022
* Goal, P, Kotani H, Yongliang Z, Reid K, Boucher JC, Savid-Frontera C, Lee SB, Beatty N, Jain MD, Davila ML; A Novel IL2Rα-/- Model for CAR-T Toxicity in Acute Lymphoblastic Leukemia Recapitulates Cytokine Release Syndrome and Neutropenia. Blood 2022; 140 (Supplement 1): 1176–1177. doi: https://doi.org/10.1182/blood-2022-165562, November 2022.
* Savid-Frontera C, Viano ME, Baez NS, et al. Exploring the immunomodulatory role of virtual memory CD8+ T cells: Role of IFN gamma in tumor growth control. Front Immunol. 2022;13:971001. Published 2022 Oct 18. doi:10.3389/fimmu.2022.971001, October 2022.
* Savid-Frontera C, Viano M, Baez N, Reynolds D, Matellon M, A Young H, Rodriguez-Galan M. Safety levels of systemic IL-12 induced by cDNA expression as a cancer therapeutic. Immunotherapy. 2021 November 16; :-. Available from: https://www.futuremedicine.com/doi/10.2217/imt-2021-0080 DOI: 10.2217/imt-2021-0080, November 2021.
* Baez N, Cerbán F, Savid-Frontera C, Hodge D, Tosello J, Acosta-Rodriguez E, Almada L, Gruppi A, Viano M, Young H, Rodriguez-Galan M. Thymic expression of IL-4 and IL-15 after systemic inflammatory or infectious Th1 disease processes induce the acquisition of "innate" characteristics during CD8+ T cell development. PLOS Pathogens. 2019; 15(1):e1007456-. Available from: https://dx.plos.org/10.1371/journal.ppat.1007456 DOI: 10.1371/journal.ppat.1007456, January 2019.